Medpace price target raised to $555 from $436 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Medpace (MEDP) to $555 from $436 and keeps a Hold rating on the shares after meeting with its management team to discuss Q3 results, book-to-bill targets, and expectations for 2026. The firm’s higher assumed forward earnings multiple at 20-tims vs. 18-times prior reflects its increased confidence in the continuing recovery in the Biotech market, the analyst tells investors in a research note.